Post-prandial Lipid Effects of Raltegravir (RAL) vs Ritonavir-boosted Darunavir (DRV-r) in Anti-retroviral Therapy (ART)-Naive Adults.

Trial Profile

Post-prandial Lipid Effects of Raltegravir (RAL) vs Ritonavir-boosted Darunavir (DRV-r) in Anti-retroviral Therapy (ART)-Naive Adults.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 09 Jun 2014

At a glance

  • Drugs Raltegravir (Primary) ; Darunavir; Emtricitabine/tenofovir disoproxil fumarate; Ritonavir
  • Indications HIV infections
  • Focus Pharmacodynamics
  • Acronyms ROaR+
  • Most Recent Events

    • 15 Apr 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Nov 2013 to 1 Dec 2014.
    • 15 Apr 2014 According to the ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.
    • 18 Oct 2012 Planned End Date changed from 1 Jul 2012 to 1 Nov 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top